Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.

Breast cancer research and treatment - 1 Sept 2013

Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa S D, Roessner A, Kalinski T, Bischoff J

Abstract excerpt

The aim of the current study was to investigate the role of BRCA1 gene aberrations in sporadic triple-negative breast cancer (TNBC) and its impact on anthracycline-based therapy. BRCA1 promoter methylation was analyzed in 70 TNBC and compared with the clinical and pathologic characteristics. As a control group, we used 70 patients with non-TNBC. BRCA1 promoter methylation was observed in 65.2 % of patients and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to DNA Methylation

Share to Lymphatic Metastasis

Share to Neoplasm Grading

Share to Triple Negative Breast Neoplasms

Share to Tumor Burden

Source

Identifiers

PMID: 24026861
DOI: 10.1007/s10549-013-2693-9

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.PMID 24026861Read ↗

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.Semantic proximity Read ↗

BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survivalSemantic proximity Read ↗

BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylationSemantic proximity Read ↗

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancerSemantic proximity Read ↗

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.Semantic proximity Read ↗

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.Semantic proximity Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.Semantic proximity Read ↗

Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.Semantic proximity Read ↗

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersSemantic proximity Read ↗

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.